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RepoRt
The Atlanta Sickle Cell Consortium represents more than 2600 
pediatric and adult patients with sickle cell disease (SCD) in the 
metropolitan Atlanta, Georgia, area receiving care at four major 
locations, each providing comprehensive care 24 hours a day, 7 
days a week. Both transfusion services that support these sites 
use two levels of prospective phenotype matching to decrease the 
rates of alloimmunization. Although exact rates are unknown 
and are currently under investigation, alloimmunization occurs 
infrequently with the exception of chronically transfused SCD 
patients, who represent the minority of active SCD patients. With 
increasing availability, red blood cell genotyping will be used 
in the near future both for determination of predicted patient 
phenotypes and for provision of genotypically matched donor 
units. Immunohematology 2012;28:24–6.
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The Atlanta Sickle Cell Consortium represents more 
than 1000 adult and 1600 pediatric patients with sickle cell 
disease (SCD) in the metropolitan Atlanta area receiving care 
at four major locations. The Aflac Cancer Center and Blood 
Disorders Service of Children’s Healthcare of Atlanta (CHOA) 
offers the largest comprehensive pediatric SCD program in the 
country, serving 1675 active patients with SCD at three sites in 
metropolitan Atlanta: Children’s at Egleston (ECH), providing 
care for 573 active patients; Children’s at Scottish Rite (SR), 
providing care for 648 active patients; and Children’s at Hughes 
Spalding (HS), providing care for 454 active patients. With 
nearly a dozen pediatric hematology faculty members from 
either Emory University or Morehouse Schools of Medicine, the 
SCD program provides 24-hour acute care, health maintenance 
services, chronic transfusion services, patient counseling 
including follow-up from newborn screening, SCD education, 
and blood and marrow transplants for eligible patients. With 
outcomes exceeding the national average, the Aflac Cancer 
Center and Blood Disorders Service has performed more blood 
and marrow transplants for patients with SCD than any other 
program in the country. To date, more than 30 children with 
SCD have been cured through matched sibling bone marrow 
transplants with a 96 percent disease-free survival rate; the 
first successful unrelated cord blood transplant for SCD was 
also performed at CHOA. In fiscal year 2010, there were a total 
of 1402 inpatient hospitalizations (ECH, 605; SR, 500; HS, 
297) and 7155 outpatient Aflac clinic visits (ECH, 2272, SR, 
2622, HS, 2261) among all sites.
Once these patients reach adulthood (age 18 and older), 
their SCD care is most often transitioned to the Georgia 
Comprehensive Sickle Cell Center at Grady Health System 
(GHS), which was the first 24-hour comprehensive primary-
care clinic for patients with SCD and has been focused on SCD 
management for more than 30 years. With 1035 active patients, 
the GHS Sickle Cell Center also provides complementary 
outpatient services including a clinic to ease the transition 
from pediatric to adult services, a multidisciplinary health 
maintenance clinic, leg ulcer and hydroxyurea clinics, 
chronic transfusion services, and other counseling and SCD 
management resources.
Transfusion support for patients with SCD at the 
previously referenced sites is provided by hospital transfusion 
services located at ECH, SR, and Grady Memorial Hospital 
under the medical direction of faculty from Emory University 
School of Medicine in collaboration with the American Red 
Cross (ARC) Blood Services, Southern Region, primary blood 
supplier of CHOA and GHS transfusion services. Although 
each blood bank has individual policies and procedures, the 
transfusion support of patients with SCD is similar across 
hospital systems.
SCD Transfusion Protocol
Children’s Healthcare of Atlanta
On receipt of a blood sample from an identified SCD 
patient, routine serologic testing including ABO and D typing 
and antibody detection and identification, if necessary, is 
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performed, similar to that for any potential transfusion 
recipient. When an SCD patient is initially seen at ECH or 
SR, a complete red blood cell (RBC) phenotype is performed 
by the ARC, which includes Rh, Kell, Duffy, Kidd, and MNS 
systems; phenotype testing is only performed if the patient has 
not been transfused within the last 3 months. The reference 
laboratory cost associated with an 11-antigen phenotype for 
C, E, c, e, K, Fya, Fyb, Jka, Jkb, S, and s is approximately $26 
per antigen for a total cost of $286 per phenotype, but prices 
will vary by institution and reference laboratory. The CHOA 
protocol for transfusion of RBCs for SCD patients consists 
of two levels of prospective phenotype matching. The first 
category of matching is reserved for children who have not 
produced a clinically significant antibody and consists of 
prospective antigen matching for Rh (D, C, E, c, e), and Kell 
(K, k) (category 1). Once a child has become sensitized and 
produced clinically significant RBC antibodies (category 2), 
RBCs for transfusion are Rh (D, C, E, c, e), Kell (K, k), Fya, and 
Jkb specific and must also be negative for any other antigens 
to which the patient has produced alloantibodies, if clinically 
significant (e.g., S, s, Jsa). In patients with a history of a warm 
autoantibody that is no longer detected by serologic testing, 
extended phenotype-matched units are provided. When the 
patient needs to be transfused, units are either ordered from 
the ARC Reference Laboratory or selected from the current 
stock of antigen-negative RBCs. RBC units for transfusion are 
all prestorage leukocyte reduced, hemoglobin S (HbS) negative, 
and as fresh as possible, preferably less than 14 days old; there 
is no requirement for irradiation. The cost for a RBC unit that 
is negative for C, E, K, and HbS is approximately $526, with 
an additional charge of approximately $80 for each additional 
antigen negative. This protocol is the same for all patients with 
SCD whether they are inpatients or outpatients and scheduled 
or urgent/emergent transfusions.
Grady Health System
When a patient with SCD is initially seen at either HS or 
GHS, the Grady blood bank performs a phenotype for C, E, 
c, e, K, Fya, Fyb, Jka, Jkb, S, and s, in addition to ABO and D 
typing, and antibody screening and identification if necessary. 
When a patient has been recently transfused, other methods 
may be needed to determine the patient’s RBC phenotype 
using either a hypotonic wash method or molecular studies; 
however, currently genotyping is typically reserved for patients 
who develop alloantibodies that do not seem physiologically 
plausible given previous phenotyping results or for patients 
who have developed uncommon alloantibodies for which no 
typing sera are available. When urgent RBC transfusion is 
necessary and a phenotype is unavailable at our institution, 
records from the ARC or referring facilities are often obtained. 
In the event the antigen profile is unknown, RBCs are 
emergently released that are negative for C, E, and K until a 
phenotype can be determined. Similar to CHOA, the GHS 
transfusion service has two levels of prospective phenotype 
matching. For patients with SCD who have not developed an 
alloantibody or autoantibody, prestorage, leukocyte-reduced, 
HbS-negative RBCs are provided that are matched for C/c, 
E/e, and K. As a cost-saving initiative, the Grady blood bank 
has developed a screening algorithm using automated RBC 
typing equipment to determine the C, E, and K status of 
donor units provided by the ARC, and we have successfully 
been able to limit costs and maintain an adequate inventory 
of units negative for C, E, and K. Once a patient has developed 
RBC alloantibodies or autoantibodies, RBC units are provided 
that are Rh (D, C, E, c, e), Kell (K, k), Fya, Jkb, and S specific 
and negative for any other antigens to which the patient has 
produced clinically significant alloantibodies; S– units are 
only provided for patients older than 16 years of age. All RBC 
units are prestorage leukocyte reduced and HbS negative. 
There is no donor unit age or irradiation requirement.
Emergency Protocols
In cases of urgent/emergent transfusion needs, it may 
not be possible to complete antibody identification, especially 
for autoantibodies and complex serologic panels, or provide 
phenotype-matched RBCs; however, in these situations direct 
consultation of the blood bank medical director and clinical 
team is crucial. At times, it is possible to delay transfusion until 
serologic studies can be completed and partially or completely 
phenotype-matched units can be provided. At minimum, 
RBC units must be antigen negative for clinically significant 
alloantibody specificities. Of course there are exceptions to 
every rule, and it is most important to treat the patient before 
protecting the integrity of prophylactic measures; it may be 
necessary to emergently release RBCs before serologic studies 
or antigen matching can be completed for patients in life-
threatening situations.
SCD Transfusion Protocol Outcomes
Outcomes in Chronically Transfused Patients at 
CHOA
Although alloimmunization rates of patients with SCD at 
CHOA have not been specifically measured, the occurrence 
of new antibodies is infrequent. Occasionally, patients are 
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transfused elsewhere without partial phenotype matching, 
and in this setting, patients have become alloimmunized. 
Alloimmunization data is available for the minority of patients 
with SCD who are chronically transfused at all three CHOA 
sites; however, it is currently being collected on all active 
SCD patients. Table 1 compares alloimmunization rates in 
the chronically transfused CHOA patients with SCD. Data 
for autoantibody formation is currently only available for the 
children at HS, and 6 (15%) patients have developed warm 
autoantibodies. Although less than 10 percent of patients 
are chronically transfused, even fewer undergo chronic 
erythrocytapheresis, which would be clinically beneficial. 
Given the current limitations of reimbursement for outpatient 
RBC exchange procedures in the state of Georgia, chronic 
RBC exchange transfusion is not a feasible option for most 
qualifying patients.
Alloimmunization Rates of GHS Patients with SCD
Of the 554 SCD patients with active blood bank records, 
139 (25%) are alloimmunized and 52 (9%) have developed 
autoantibodies, thus requiring extended phenotype-matched 
units. However, this most likely represents an overestimation 
of alloimmunization as data were obtained from active blood 
bank records and many of these SCD patients were likely 
transfused prior to the initiation of prospective phenotype-
matching programs. In addition, 20 of these patients have 
tracking notes in the blood bank information system that 
require a medical director’s consult before issuing any RBC 
units; these patients have either complex alloantibodies or 
a history of hemolytic or unexplained severe transfusion 
reactions. Under these circumstances, there is most often a 
conversation between the transfusion service medical director 
and hematology attending physician to weigh the risks and 
benefits of transfusion in this select group of SCD patients.
Conclusions
Two major academic medical centers in Atlanta, Georgia, 
CHOA and GHS, provide comprehensive care to more than 
2600 pediatric and adult patients with SCD. The transfusion 
services that support these sickle cell centers of excellence 
use two levels of prospective phenotype matching to prevent 
alloimmunization. Although alloimmunization rates are 
currently under investigation, most patients are infrequently 
alloimmunized with the exception of chronically transfused 
patients with SCD. As genotyping becomes more widespread, 
increased adoption of genotyping patients with SCD and 
provision of genotypically matched RBC donor units will 
become a possibility; CHOA will embark on prospective 
genotype matching in 2012. 
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Table 1. Alloimmunization statistics of chronically transfused 
patients with sickle cell disease
Site












Egleston 573 48 (8.4) 12 (25) 0
Hughes Spalding 454 39 (8.6) 10 (25.6) 1
Scottish Rite 648 45 (6.9) 19 (42.2) 5
